Zeria Pharmaceutical Co., Ltd

Employee trend (consolidated)

Note: GlobalData reports 1,746 consolidated employees against an unspecified reference date; the company's own outline page reports 1,748 as at 31 March 2026. The parent-company and prior-year headcounts above are drawn from filing aggregator summaries; the precise FY2024 and FY2025 splits should be confirmed against the respective Annual Securities Reports before use in a published document. Headcount has been essentially flat for three years, which is itself the notable fact: Zeria has grown revenue roughly 18% over that period without material headcount addition, with growth carried by European subsidiary productivity and price/mix rather than sales-force expansion.

Positioning statement (150 words)

Zeria Pharmaceutical is a mid-capitalisation Japanese pharmaceutical company that has executed one of the more complete internationalisation transitions in its peer group. Founded in 1955 around a chondroitin preparation, it built a dual-engine model — prescription gastroenterology plus consumer self-medication — and then, through the 2009 acquisition of Switzerland's Tillotts Pharma AG and the 2020 purchase of Dificlir's European marketing authorisations from Astellas, converted itself from a domestic specialist into a company that now earns 59.3% of revenue outside Japan. Ranked 23rd by revenue among 35 major listed Japanese pharmaceutical companies, it nonetheless posts a 13.9% operating margin that exceeds most similarly sized peers, several of which recorded operating losses in FY2026. The strategic question is no longer whether Zeria can globalise, but whether it can replace Dificlir — its second-largest product, facing patent expiry inside the current medium-term plan — before the earnings contribution rolls off.

2.1 What the company does

Zeria Pharmaceutical researches, develops, manufactures, imports, exports and sells pharmaceuticals, quasi-drugs, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals and reagents; and cosmetics, health foods, alcoholic and soft beverages, food additives, feed, fertiliser, hygiene sundries, medical devices, health equipment, sanitary fixtures, beauty appliances, and measuring and analytical instruments. That is the articles-of-incorporation description; in economic substance the group does two things, and a rounding error.

The prescription business is a gastroenterology franchise. Zeria describes its ethical-drug strategy as specialising "from research and development through to sales in the gastrointestinal field, covering the upper to lower gastrointestinal tract," with oncology selected as the second focus area behind gastroenterology. In Japan the company fields its own MR (medical representative) organisation through seven branch offices; in Europe it sells through the wholly owned Tillotts Pharma network of nine legal entities; in Asia it exports and works through the Vietnamese subsidiary F.T. Pharma and third-party distributors.

The consumer healthcare business manufactures, procures and sells OTC medicines, health foods, quasi-drugs and cosmetics supporting self-medication. It is overwhelmingly a Japanese business, anchored on three brand families — Hepalyse (liver-hydrolysate tonics and drinks), Chondroitin (joint and back-pain preparations), and With One (botanical laxatives) — supported by dermatology, oral care, Western herbal medicines and the Iona cosmetics line.

The "Other" segment is insurance agency and real-estate rental income, generating ¥151m in FY2026 — 0.17% of group revenue. It is not investible and exists largely as a legacy holding structure.

2.2 Business model and revenue model

Zeria's revenue is essentially 100% product sales. There is no meaningful service, subscription or SaaS-analogue revenue. Licensing income exists but is not separately disclosed at a level suggesting materiality; the Z-338/acotiamide out-licensing programme to Faes Farma, Meiji Seika Pharma, Agastra-Lab and others generates milestone and royalty flows that are absorbed into segment results without separate line-item disclosure.

Revenue is recognised on customer acceptance for most transactions, and on shipment for domestic sales where the shipment-to-acceptance interval is normal. Consideration is measured net of returns, discounts and rebates; variable consideration is estimated to the extent significant reversal is improbable. Customer loyalty points issued by certain subsidiaries are identified as separate performance obligations. Consideration is collected within one year, so there is no significant financing component.

Two structural features of the model deserve emphasis:

First, the gross margin is very high and the operating margin is not. FY2026 gross margin was 73.1%; operating margin was 13.9%. The 59-point gap is SG&A, which ran at ¥52,808m, or 59.2% of revenue. This is a marketing-intensive, not a manufacturing-intensive, business. Advertising and promotion alone is budgeted at ¥3,100m for FY2027 against ¥2,440m spent in FY2026 — a 27% planned increase.

Second, a substantial share of the group's economic value sits in acquired intangibles rather than in tangible plant. At 31 March 2026, intangible fixed assets stood at ¥39,582m — 22% of total assets and 43% above the ¥27,599m carrying value of all tangible fixed assets. Of that, ¥27,089m is marketing rights (販売権) and ¥7,822m is trademarks. The marketing-rights balance is dominated by the Dificlir authorisations acquired from Astellas. This is the single most important balance-sheet fact about Zeria, and Section 18 returns to it.

2.3 Value chain position, customers and end markets

Zeria occupies the branded-originator and in-licensor position. It is not a generic manufacturer, not a CDMO, and not a wholesaler. It sits between upstream API and contract manufacturing (a dependency demonstrated in FY2026, when a contract manufacturer's production-equipment fault caused an Asacol supply shortage that suppressed overseas sales through Q3) and downstream distribution.

Customer types by channel:

• Japan ethical: pharmaceutical wholesalers supplying hospitals, clinics and dispensing pharmacies. Reimbursement is set by the national NHI price list, which is revised on a schedule that has become effectively annual — a recurring negative disclosed in every recent results commentary.
• Europe ethical: national wholesalers and, in tender markets, hospital and payer procurement bodies, served through Tillotts entities in the UK, Ireland, Sweden, Denmark, Germany, France, Spain, Italy and the Czech Republic.
• Japan consumer: drugstore chains, dispensing pharmacies, convenience-store chains (a distinct and strategically important channel for the Hepalyse W range), general merchandise retailers, and a direct-to-consumer e-commerce operation (Zeria Online).
• Asia: distributors, plus F.T. Pharma's own domestic Vietnamese channel including a new infusion-solution plant.

End markets served: inflammatory bowel disease (ulcerative colitis, Crohn's disease); Clostridioides difficile infection; functional dyspepsia; gastritis and peptic ulcer; iron-deficiency anaemia; hyperkalaemia; hypophosphataemia; hypertension; pain and inflammation; ophthalmology; underactive bladder (development stage); non-small-cell lung cancer (development stage); and the Japanese self-medication market across tonics, digestive health, joint health, constipation, cold remedies, dermatology, oral care, femcare and cosmetics.

2.4 Independent characterisation

Read without the company's framing, Zeria is best understood as a Japanese-listed holding structure around a European specialty gastroenterology business, cross-subsidised and de-risked by a mature, cash-generative Japanese consumer brand portfolio.

The numbers support this reading more strongly than the company's own "two wheels of a cart" (車の両輪) balanced-portfolio narrative. In FY2026 the ethical segment produced ¥61,626m of revenue and ¥12,176m of segment profit; consumer healthcare produced ¥27,382m and ¥6,360m. But ethical is where all the growth is (+4.5% versus −2.8%), and within ethical, overseas is where all of that growth is: Japan revenue fell 3.4% to ¥36,318m while overseas rose 6.3% to ¥52,841m. The Japanese consumer business is a declining-to-flat annuity that funds European expansion and absorbs corporate overhead; the interesting asset is Tillotts.

This matters for valuation because the market appears to be pricing the consolidated entity as a Japanese mid-cap OTC company — 0.85x book, ~9x forward earnings — rather than as a European specialty pharma with a 22% EBITDA margin and a 59% net-debt-to-EBITDA ratio. The counter-argument, which the market may be right about, is the Dificlir patent cliff.

10.1 Stated corporate strategy — verbatim themes

From the Annual Securities Report for the 72nd term (FY2026), management policy section:

Management policy: Based on "health creation is happiness creation," as a comprehensive health company, contributing to improvement of quality of life through R&D, manufacture and sale of pharmaceuticals meeting international medical needs and consumer healthcare products oriented to self-medication.

Management strategy: The group's characteristic is balanced management through the Ethical Pharmaceuticals Business and the Consumer Healthcare Business. Two core businesses contributing to earnings by leveraging their respective strengths brings sustainable growth. Further, this stable management base makes possible M&A for the next growth stage and the development and launch of new drugs, which require large expense and long years.

The company frames its growth strategy publicly under three headings: BALANCE (a well-balanced portfolio across the two core segments), FOCUS (concentrated resource deployment into areas of strength — gastroenterology in prescription, self-medication in consumer), and GLOBAL (expansion through M&A and alliances).

Key performance indicators: management states it prioritises consolidated revenue, consolidated operating income, and consolidated return on equity.

10.2 The 11th Medium-Term Management Plan (FY2024–FY2026) — outcome

10.3 The 12th Medium-Term Management Plan (FY2027–FY2029) — launched May 2026

Quantitative targets for FY2029 (the company's "2028年度"):

• Consolidated revenue: ¥100.0bn
• Consolidated ROE: 10% or higher

Against FY2026 actuals of ¥89,159m and 8.5% ROE, this implies a 3.9% revenue CAGR over three years [derived] — a deliberate deceleration from the 10.6% delivered over the prior four years, and an explicit acknowledgement of the Dificlir cliff. The plan states directly: "During the 12th Medium-Term Plan period, the patent for Dificlir, which drove performance in the previous plan, will expire and generic entry is anticipated."

Three key points:

1. Further expansion of global deployment.

• Europe: accelerate licensing activity to acquire "a new product that can leverage our strengths, including a strong proprietary sales network covering Europe broadly," to become the growth driver succeeding Dificlir. For existing products: maximise Asacol through 800mg growth in the UK and other principal markets plus further expansion of the 1600mg high-dose presentation; minimise the negative impact of the anticipated Dificlir patent cliff; expect gradual Entocort decline from generics while expanding in generic-free countries.
• Asia: expand the number of export countries for Zeria products; promotional activity and needs-based product development with local distributors; early market establishment for F.T. Pharma's new infusion-solution business; expand exports to neighbouring countries.

2. Return both domestic businesses to a growth trajectory.

• Ethical: concentrate sales resources on substantially expanding Veltassa's share. Supporting evidence cited: sodium-free calcium-exchange formulation; once-daily oral dosing; inclusion in the 2025 revised Japanese heart-failure guideline and the 2025 hypertension management guideline; the Japanese hyperkalaemia market growing 18.9% year on year on an NHI-price basis (IQVIA JPM, April 2024–March 2026) and estimated patient numbers up 9.6% (JMDC social-insurance claims database, FY2024); and the 1 December 2025 lifting of the dosing-period restriction. Digital marketing including web lectures targeted at nephrology, dialysis and cardiology specialists.
• Consumer: grow Hepalyse and Chondroitin as core; maximise market awareness for Hi Jelly, Masdent and Western herbal products through advertising investment; expand the customer base via femcare and mail-order/direct sales; accelerate development speed; introduce needs-matched products including Western herbals, new switch-OTC and direct-OTC products, and foods with function claims.

3. Enhancement of the development pipeline. Continue development of proprietary acotiamide and Z-100 and examine new indications; actively in-license new development candidates; create evidence for marketed products through database research and support for investigator-initiated clinical research.

10.4 Capital allocation policy

The 12th Plan sets out an explicit cash-allocation framework — a first for Zeria and a direct response to TSE's "management conscious of cost of capital and share price" initiative.

The R&D envelope of ¥15–20bn over three years compares with ¥11.5bn actually spent over FY2024–FY2026, implying a 30%–74% increase in R&D intensity [derived]. FY2027 guidance already embeds ¥5,000m of R&D against ¥3,709m in FY2026 (+34.8%).

The conspicuous omission is buybacks. The shareholder-return line reads "continuous and stable dividends" only. Given a 0.85x price-to-book and ¥12.2bn of treasury stock on the balance sheet, this is a notable choice.

10.5 Medium-term financial guidance

H1 FY2027 guidance: revenue ¥45,000m (+12.6%), operating income ¥6,000m (+64.8%), ordinary income ¥6,000m (+125.9%), net income ¥4,000m (+130.2%). The very large percentage increases reflect a weak H1 FY2026 comparison base.

10.6 Other announced initiatives (last 24 months)

• Executive officer personnel changes announced 9 May 2025 and 9 April 2026.
• Director candidate slate announced 8 May 2026, including the first female outside director.
• Product price revisions announced 3 March 2025 and 30 March 2026 — a recurring inflation pass-through mechanism in the consumer business.
• Shareholder-benefit programme expanded January 2025 (adding a long-holding preferential tier delivering Hepalyse W Premium Kiwami) and course contents revised March 2026.
• Sustainability Committee established, chaired by the director responsible for the Administration Division, with subordinate working groups.
• TCFD-aligned disclosure introduced in the FY2026 Annual Securities Report.
• Health & Productivity Management: certified as a Health & Productivity Management Outstanding Organization 2026 (Large Enterprise Category).
• Kurumin certification obtained in 2025 under the Act on Advancement of Measures to Support Raising Next-Generation Children.
• Disaster relief support provided for the 2024 Noto Peninsula earthquake (January 2024) and the 2026 Kumamoto earthquake (August 2026).

5.1 Ethical Pharmaceuticals — disclosed product revenue (¥ million)

5.2 Consumer Healthcare — disclosed brand-family revenue (¥ million)

5.3 Ethical portfolio — product by product

Asacol (mesalazine, 5-ASA) — ulcerative colitis. The largest product in the group at ¥24,303m, 39.4% of ethical-segment revenue and 27.3% of consolidated revenue. A pH-dependent modified-release oral formulation. Zeria licensed Japanese rights from Tillotts in January 2004 and launched Asacol Tablets 400mg domestically in December 2009; the 2009 acquisition of Tillotts brought global control of the asset. A new dosage and administration was approved in Japan in May 2017. The strategic driver is the high-dose 1600mg tablet, which management explicitly identifies as the growth engine alongside the incumbent 800mg presentation; principal markets are the United Kingdom, France, Germany and Spain. An exclusive Chinese arrangement was reported in November 2024 alongside the Tillotts–Pioneer Pharma agreement. Pricing model: prescription, reimbursed at national list prices; no unit pricing disclosed.

Dificlir (fidaxomicin) — Clostridioides difficile infection. Japanese trade name Dafclir. ¥22,588m in FY2026, 36.7% of ethical revenue, and the fastest-growing product in the group's history: revenue rose from ¥260m in FY2021 to ¥22,588m in FY2026, a 143% CAGR [derived]. A macrocyclic antibiotic recommended as a first-line agent in European infectious-disease guidelines. Tillotts acquired the EMEA and CIS marketing authorisations from Astellas Pharma Europe in November 2020; Zeria took over the Japanese marketing approval for Dafclir Tablets 200mg from Astellas in April 2023. Principal markets are France, Germany, the United Kingdom and Spain. Critical caveat: in Q1 FY2027 the company shortened the amortisation life of the Dificlir marketing rights because the probability of generic entry had increased, reducing quarterly operating income by ¥389m. The 12th Medium-Term Plan explicitly names Dificlir patent expiry as the central challenge of the plan period.

Entocort (budesonide) — inflammatory bowel disease / Crohn's disease. Japanese trade name Zentacort. ¥5,246m in FY2026, 8.5% of ethical revenue, declining 2.4%. A locally acting corticosteroid. Tillotts acquired worldwide ex-US rights from AstraZeneca in July 2015; Zentacort Capsules 3mg launched in Japan in November 2016. Generics have entered in several European markets, and management guides to gradual decline with mitigation via expansion in generic-free countries.

Acofide (acotiamide, Z-338) — functional dyspepsia. ¥3,080m in FY2026, 5.0% of ethical revenue. Zeria's flagship in-house new chemical entity and an upper-gastrointestinal motility enhancer. Launched in Japan June 2013 after a 2002 co-development agreement with Yamanouchi; co-promotion with Astellas ended January 2021. This is the asset Zeria is globalising by out-licence rather than by direct investment — see Section 12.

Veltassa (patiromer sorbitex calcium, ZG-801) — hyperkalaemia. Launched in Japan March 2025 as Veltassa Powder for Suspension 8.4g sachets. In-licensed from Vifor (now CSL Vifor) under a March 2018 exclusive Japanese agreement. Not separately disclosed in the product table; contributes within "Other ethical." Product differentiators as positioned by management: sodium-free calcium-exchange polymer, once-daily oral administration. Cited in the 2025 revision of the Japanese Circulation Society / Japanese Heart Failure Society heart-failure guideline and in the Japanese Society of Hypertension's 2025 hypertension guideline. The dosing-period restriction was lifted on 1 December 2025, removing the principal commercial constraint. This is the single most important domestic growth item in the 12th Medium-Term Plan.

Ferinject (ferric carboxymaltose) — iron-deficiency anaemia. Launched September 2020, in-licensed from Vifor (International) AG. Marketed to gastroenterology and obstetrics/gynaecology. Zeria has invested in real-world-evidence database studies and specified clinical research to build post-marketing evidence.

Other disclosed ethical products (not individually broken out in revenue): Promac (polaprezinc), a zinc-containing anti-ulcer agent, available as Promac Granules 15% and Promac D Tablets 75; Marzulene series for gastritis and ulcer; Acinon (nizatidine) tablets 75mg/150mg for gastritis and ulcer; Visiclear Tablets, oral bowel-cleansing agent for colonoscopy preparation; Hosribon Combination Granules for hypophosphataemia; Landel Tablets (efonidipine), long-acting calcium channel blocker; Peon Tablets (zaltoprofen), oral NSAID; Answer 20 Injection (Z-100) for leukopenia suppression after radiotherapy; Polidocasklerol, sclerosant for varicose veins; a non-steroidal anti-inflammatory ophthalmic solution; a proton-pump inhibitor; and topical anti-inflammatory circulation enhancers. Company disclosure describes the ethical portfolio as covering "upper to lower gastrointestinal tract" indications comprehensively.

5.4 Consumer Healthcare portfolio — brand by brand

Hepalyse group — ¥13,255m, 48.4% of CHC revenue. The group's largest consumer franchise, built on liver hydrolysate. It splits into two economically distinct halves that the company now discloses separately:

• Medicinal Hepalyse (¥7,306m, +13.6%): New Hepalyse, Hepalyse Plus II, Hepalyse Drink II, Hepalyse Hi Plus, Hepalyse King Plus, Hepalyse King EX, and the FY2026 launches Hepalyse Gastrointestinal Oral Liquid EX (designated quasi-drug, September 2025) and Hepalyse Gastrointestinal Drink (designated quasi-drug, October 2025). Positioning has been broadened from hangover/fatigue to "nutritional supplementation during colds and gastrointestinal upset" — a deliberate and, on the evidence, successful category expansion.
• Hepalyse W and others (¥5,948m, −2.8%): the convenience-store channel range, including Hepalyse W, W Hyper, W Sparkling, W Premium, W Premium Kiwami, W Shine (October 2024), W Jelly, Hepalyse Super Rich, and export-market variants including Hepalyse WT for Taiwan (FY2026 launch). Management attributes the decline to slowing category growth. In Q1 FY2027 this sub-family returned to growth, driving the Hepalyse group up 4.9%.
• Cumulative milestone: Hepalyse family sales passed ¥10.0bn in March 2016; they are now ¥13.3bn.

Chondroitin group — ¥5,427m, 19.8% of CHC revenue. Chondroitin ZS Tablets (the founding franchise, launched December 1964), Chondrobe, Chondro Amino Ca Tablets (October 2020), Chondrobi Concentrated Liquid Junko, Zeria ZS Supporter (supports, nationwide July 2019), and Chondro Support Active (FY2026 launch). Family sales passed ¥5.0bn in March 2006 and have been broadly flat for two decades. Television advertising has been used continuously since June 2008. The upstream API is manufactured in-house by ZPD A/S in Denmark — genuine vertical integration and a real cost advantage.

With One group — ¥1,460m, 5.3% of CHC revenue. Botanical laxatives: With One (1987), With One Plus (2004), New With One (January 2012, TV-supported from March 2012), With One Suppository (September 2016).

Western herbal medicines — a strategically emphasised sub-portfolio with high margin and regulatory differentiation: Prefemin for premenstrual syndrome (September 2014; re-examination completed and reclassified to Category 2 OTC April 2023); Belfemin for leg oedema from mild venous return disorder (approval November 2020, launch December 2021; migrated to Category 1 December 2024 and to Category 2 December 2025); Colpermin for irritable bowel syndrome (approval August 2021, launch March 2022; migrated to Category 1 September 2025). Management identifies femcare as a target market for customer-base expansion.

Other consumer products — ¥7,241m, 26.5% of CHC revenue, −15.1%. This category contains: Hi Jelly / Hi Jelly Granule EX (royal-jelly tonic; the original Hi Jelly Powder dates to January 1978) and Hi Jelly FE; the Masdent medicated toothpaste family; the Prevarin dermatological range including Prevarin α Quick Ointment and Cream (November 2023) and Prevarin My Care (June 2020); Sepy cold-remedy and throat/nasal-spray range including Sepy IP Cold Gold Tablets and Granules; Beauclear eye drops including Beauclear Hi40 Active and Beauclear AG Fresh, and AZ antibacterial eye drops; Stomase and Stomacool digestive preparations; Dolmine H Suppository for haemorrhoids; New Lecicarbon suppository laxatives; Magic Hand Cream (March 2019) and Magic Barrier Disinfectant Spray (August 2022); Indometho Hot Pass plasters; and food for specified health uses. Management named Prevarin and Masdent specifically as the products losing share to competitors in FY2026.

Iona cosmetics (through Iona International Co., Ltd.): Iona F skincare (design refresh December 2024, and Iona F Night Wrapping Pack launched September 2025), Iona Spa & Mineral (Essence Gel, Essence Gel EX, W Cleansing), and Iona R Double Action Cream (FY2026 launch). In March 2026 Zeria announced the transfer of Iona product sales operations and of the "Iona Club" customer programme administration — a restructuring signal worth monitoring.

Direct channel: Zeria Online, the group's own e-commerce operation. Management identifies mail-order and direct sales as a growth priority in the 12th Medium-Term Plan for improving customer access. The channel suffered a system failure from late October 2025 with partial restoration in November 2025 and full restoration announced 6 April 2026.

All figures JPY millions, J-GAAP consolidated, fiscal years ended 31 March.

6.1 Income statement

EBITDA is derived as operating income plus depreciation and amortisation from the cash flow statement plus goodwill amortisation charged above the operating line. FY2023 R&D is derived from the disclosed FY2024 growth rate of +7.8%. Advertising and promotion is disclosed only from FY2026 in the results presentation.

6.2 Per-share and margin metrics

No dilutive potential shares exist; the company has no stock options outstanding, so basic and diluted EPS are identical.

Revenue CAGR FY2022–FY2026: 10.6%. Revenue CAGR FY2021–FY2026: 11.1%. Operating income CAGR FY2022–FY2026: 18.1%. [all derived]

6.3 Balance sheet

Interest-bearing debt as defined here comprises short-term and long-term borrowings; lease obligations sit within "other" liabilities and are not separately quantified.

6.4 Cash flow

6.5 Ratio analysis

ROE, ROA on ordinary income, equity ratio and interest coverage are as disclosed by the company. ROIC, DSO, DIO, DPO and CCC are derived by this analyst. Interest coverage is calculated by the company as operating cash flow divided by interest paid.

6.6 Commentary on trends, inflections and drivers

Revenue. The five-year record is one of exceptional growth followed by an abrupt stall. Revenue compounded at 10.6% from FY2022 to FY2026, with four consecutive record years — but the FY2026 increment was only ¥1,848m (+2.1%) against ¥11,586m (+15.3%) in FY2025. Two identifiable causes: the Asacol supply interruption at a contract manufacturer, which suppressed European sales for three quarters; and the deterioration of the domestic consumer business. The inflection is not a demand inflection; Q1 FY2027 revenue rose 10.1% once supply normalised, with Asacol up 17.9%. Investors should treat FY2026 revenue as understated relative to trend and FY2027's guided 6.6% as the more honest run-rate.

Gross margin has been remarkably stable in a 70.8%–73.3% band, expanding 230bp over the period as mix shifted toward higher-margin European prescription products. The FY2026 10bp contraction is noise, not a signal, though energy and raw-material cost inflation is a stated and continuing headwind.

Operating income grew faster than revenue in three of five years, lifting the margin from 10.7% to 13.9%. FY2026 broke that pattern: operating income rose only 1.4%. The bridge disclosed by management is instructive — the positive was the non-recurrence of a Dificlir milestone payment booked in FY2025 commissions; the negatives were wage increases and overseas subsidiary headcount, intensified overseas promotional activity, overseas core-system investment, and European pharmaceutical tax-regime changes. Two of those four are structural.

Below the operating line is where the noise lives. Ordinary income fell 14.0% in FY2026 despite operating income rising, purely because a ¥634m FX gain in FY2025 became a ¥1,356m FX loss in FY2026 — a ¥1,990m swing. The same mechanism ran in reverse in FY2025 (+50.8% ordinary income on +26.8% operating income). Q1 FY2027 repeated the pattern: operating income +28.3%, ordinary income −13.8%, on a ¥644m FX loss driven by Swiss franc strength against the euro and sterling. This is the defining analytical trap in Zeria's reported numbers. The exposure is not primarily yen-denominated; it arises inside the European operating structure, where a Swiss-franc functional-currency parent holds euro and sterling receivables. Management's FY2027 guidance assumes zero FX gain or loss, which is why guided ordinary income growth (+17.7%) exceeds guided operating income growth (+5.1%).

Net income fell 14.9% in FY2026 to ¥8,455m. Beyond the FX effect, the effective tax rate rose from 21.0% to 24.8%. The FY2023 rate of 14.7% was anomalously low and should not be used as a baseline.

Balance sheet transformation is the strongest part of the story and the most under-appreciated. Over five years, net debt fell from ¥40,525m to ¥11,344m — a 72% reduction — while total assets grew 45%. Net debt to EBITDA compressed from 3.4x to 0.58x. The equity ratio rose 16.1 points to 60.3%. This deleveraging paid down the debt raised to finance the ¥15.4bn Dificlir rights acquisition in FY2021. Two caveats: first, ¥7,632m of the FY2026 equity increase was foreign-currency translation adjustment and ¥3,927m was remeasurement of defined benefit plans — that is, ¥11,559m of the ¥18,808m net-asset increase was other comprehensive income, not earned profit. Second, short-term borrowings of ¥33,834m remain the dominant debt instrument, so the reported "long-term borrowings ¥5,270m" understates refinancing dependence.

The net defined benefit asset deserves scrutiny. It rose from ¥13,265m to ¥19,295m in FY2026 — a ¥6,030m increase, equivalent to 71% of net income for the year. This flows through OCI and inflates book value without generating cash. Any adverse move in discount rates or plan-asset returns reverses it. Analysts computing tangible book value should note that goodwill (¥3,028m), marketing rights (¥27,089m), trademarks (¥7,822m) and the pension asset (¥19,295m) together total ¥57,234m against owners' equity of ¥108,397m.

Cash flow deteriorated in FY2026 and this is the genuine warning sign. Operating cash flow fell 23.0% to ¥9,956m even though pre-tax income fell only 11.2%. The drivers were a ¥3,423m inventory build (versus ¥1,647m the prior year), a ¥1,896m receivables increase, and a ¥2,738m tax payment (versus ¥1,001m). Free cash flow fell 30.7% to ¥7,060m. The working-capital position is the most concerning line in the accounts: the cash conversion cycle extended by 65 days in a single year to 372 days, driven by days inventory outstanding rising from 257 to 318 and DSO from 112 to 129. Some of this is deliberate safety stock after the Asacol supply failure — a rational response — but 318 days of inventory is high even for a pharmaceutical company with a 27% cost-of-sales ratio, and it should be monitored quarterly. Q1 FY2027 showed further inventory build (+¥1,631m) partly offset by a ¥5,072m receivables reduction.

Capital intensity is modest. Capex has averaged ¥2,722m over five years, or 3.4% of revenue — below depreciation of ¥6,455m average, which itself is dominated by amortisation of acquired intangibles rather than replacement of physical assets. This means reported depreciation substantially overstates maintenance capital requirements, and free cash flow understates distributable cash — a favourable distortion that partly offsets the unfavourable working-capital picture.

22.1 Management guidance

FY2027 (year ending 31 March 2027), reaffirmed 6 August 2026 after Q1:

Medium term (FY2029, the final year of the 12th Plan): revenue ¥100.0bn; ROE ≥10%. Three-year cumulative pre-R&D operating cash flow of ¥77.0bn; three-year R&D spend of ¥15.0–20.0bn.

Q1 FY2027 progress: revenue of ¥21,449m is 22.6% of the full-year target; operating income of ¥1,951m is 15.0%. Both consistent with a first-quarter-light seasonality. Management stated revenue and operating income were broadly on plan, and that ordinary and net income fell short solely because of the ¥644m FX loss, which guidance does not embed.

22.2 Consensus expectations

The IFIS consensus for FY2027 ordinary income was approximately ¥12,500m as at 8 May 2026 — 4% below company guidance of ¥13,000m [derived]. The consensus was 16.2% below the FY2026 outturn, so the analyst community has recently been positioned conservatively and been wrong in the company's favour. Q1 FY2027 ordinary income missed consensus. The number of covering analysts and their current estimates are not verified.

22.3 Bull case

1. The FY2026 stall was mechanical, not structural, and FY2027 re-rates on evidence. Asacol's overseas weakness was a contract-manufacturer equipment fault, not demand. Once supply normalised, Asacol grew 17.9% in Q1 FY2027 and the ethical segment grew 13.5%. If the group delivers the guided ¥95.0bn and ¥13.0bn, the stock at 9.2x forward earnings and 0.85x book is being asked to prove very little. On peer-average multiples for a 14% operating margin business — even conservatively, 12x forward earnings — the shares would be worth roughly ¥2,720 [analyst estimate].

2. Veltassa is a genuinely asymmetric domestic option that costs nothing to own. The Japanese hyperkalaemia market is growing 18.9% by value with patient numbers up 9.6%. The dosing-period restriction lifted on 1 December 2025. The product appears in two 2025 guideline revisions. Zeria already carries the MR fixed cost. Every yen of Veltassa revenue drops through at close to incremental gross margin. The domestic ethical business is small enough (roughly ¥8.8bn) that even a ¥3–5bn Veltassa franchise transforms its economics and reverses the −3.4% domestic revenue trajectory.

3. Balance-sheet capacity is unusually large relative to market capitalisation, and management has now committed to using it. Net debt of ¥11.3bn against ¥19.7bn of EBITDA, a 60.3% equity ratio, and ¥77.0bn of three-year pre-R&D operating cash flow, against a market capitalisation of ¥91.6bn. The 12th Plan explicitly targets acquiring a European growth driver. A ¥30–50bn in-licensing or product-rights transaction — the size of the 2020 Dificlir deal, which Zeria executed successfully and has since paid down entirely — would be comfortably financeable [analyst estimate]. Zeria has done this before and it worked: Dificlir went from ¥260m to ¥22.6bn in five years.

22.4 Bear case

1. Dificlir is 25.3% of revenue and the cliff has already started. The Q1 FY2027 useful-life shortening is not an accounting technicality; it is management telling the market that generic entry is more probable and nearer than previously modelled. The Entocort precedent shows what follows: −0.8%, then −2.4%, with management guiding to continued decline. Applied to Dificlir, a 40% revenue erosion over three years removes ¥9bn of revenue at very high incremental margin — potentially ¥5–7bn of operating income against a base of ¥12.4bn [analyst estimate]. The ¥100bn FY2029 revenue target requires ¥11bn of growth net of that erosion, from a company whose entire pipeline is one molecule.

2. The replacement product does not exist yet, and the company has not transacted in six years. The 12th Plan's first pillar is to acquire a successor. As at August 2026 no target has been named. Zeria's last operating-company acquisition was in 2020; its last major product-rights acquisition was in 2020. In-licensing markets for de-risked European specialty assets are competitive and expensive, and Zeria is bidding against better-capitalised buyers. If nothing is signed by FY2028, the plan's revenue bridge is unbuildable.

3. Cash generation is deteriorating while the reported balance sheet improves. Operating cash flow fell 23.0% in FY2026 to ¥9,956m; free cash flow fell 30.7%. The cash conversion cycle extended 65 days in a single year to 372 days. Meanwhile 61% of the FY2026 equity increase was other comprehensive income — currency translation and pension remeasurement — not earned profit. The 60.3% equity ratio and 0.58x net-debt-to-EBITDA that make the bull case for transaction capacity are partly a function of a weak yen and a favourable discount-rate environment, both of which can reverse. And on the profit and loss account, R&D is guided up 34.8% and advertising up 27.0% in FY2027 while revenue grows 6.6% — the operating leverage is running the wrong way.

22.5 Catalysts and monitorables for the next twelve months

22.6 Analyst verdict (300 words)

Zeria Pharmaceutical is a well-run, unusually profitable mid-cap that has successfully executed a strategy most of its Japanese peers only talk about — and is now valued as though it had not.

The facts on execution are not seriously disputable. Overseas revenue went from 36.2% to 59.3% of the total in five years. Revenue compounded at 10.6%, operating margin expanded 320 basis points to 13.9%, and net debt fell 72% while the equity ratio rose to 60.3%. Both of Zeria's closest revenue peers lost money at the operating line in FY2026. The stock trades at 0.85x book, near the bottom of a sixteen-year range, and 9.2x forward earnings.

The market's scepticism is not irrational, however. It is concentrated on one number: Dificlir is 25.3% of revenue, its patent expires inside the current plan period, and the company has already begun accelerating amortisation of the ¥25.9bn of marketing rights that represent it. Zeria's answer — acquire a replacement for the Tillotts network — is strategically correct, financeable, and unexecuted. Its supporting answer, a domestic Veltassa ramp, is genuinely attractive but unproven and undisclosed. Its pipeline answer is one molecule and a 4.2% R&D ratio that ranks 27th of 29 domestic peers.

The correct framing is therefore not "cheap versus expensive" but "how much time does the balance sheet buy?" With 0.58x net debt to EBITDA and ¥77bn of three-year pre-R&D operating cash flow, the answer is: several years, and enough capacity for a transaction the size of the one that created Dificlir in the first place.

Zeria has done exactly this before, successfully. The investment case rests on whether the same management — a 54-year-tenured Chairman and his son, with no equity-linked incentive and no nomination or remuneration committee — will do it again, and in time.

End of dossier. Figures marked [derived] are calculated by this analyst from disclosed primary data; figures marked [analyst estimate] are judgemental. Items marked "not publicly disclosed" or "not verified" should be sourced directly from the FY2026 Annual Securities Report (72nd term, filed 25 June 2026) or from the company's Investor Relations department before publication.

Chronological register, February 2025 to August 2026. 34 entries. Layoffs/hiring:* no restructuring programmes, layoffs or material hiring announcements were disclosed in the period. Consolidated headcount was essentially unchanged. Wage increases are cited as a cost driver, consistent with the broad Japanese shunto environment.